MICRONAUT-S MRSA/GP

Destaques

Phenotypic resistance detection amongst gram-positive pathogens

In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-positive pathogens. This has impacted both hospital and community acquired infections.

MICRONAUT-S板块设计提供routine laboratory with an efficient tool for phenotypic detection of the important resistance mechanisms among these bacteria. The MICRONAUT-S MRSA/GP also includes highly effective backup antibiotics: ceftaroline, daptomycin, linezolid, tigecycline, vancomycin, and teicoplanin.

Susceptibility Testing

The susceptibility testing is based on the rehydration of antibiotics by adding a standardized bacteria suspension (Mueller Hinton Broth, cation adjusted (CAMHB)). The result is measured photometrically after 18-24 hours incubation at 35-37°C. Results are measured and interpreted either with the MICRONAUT software or visually.

Due to a special vacuum drying method, the plates can be stored at a room temperature of 15-25°C. The MICRONAUT test plates have a shelf life of 24 months at date of production.

Características

Antibiotic configuration for the detection of single or multi-resistances of gram-positive bacteria in nosocomial infections

The antibiotics configuration of the MICRONAUT-S MRSA/GP plate allows the specific detection of the clinically relevant single or multi-resistances of gram-positive bacteria in nosocomial infections.

The susceptibility testing with highly effective reserve antibiotics like ceftaroline offers the user alternatives in case of extreme multi-resistance. The MICRONAUT-S MRSA/GP offers the following features and benefits.

Susceptibility testing of Staphylococci

Penicillin G MIC: detection of staphylococcal penicillinases
Detection of MRSA resistance phenotype by MIC determination of oxacillin and cefoxitin
Detection of oxacillin borderline resistance phenotype (BORSA) by detection of cefoxitin susceptibility
Detection of the induced MLSB resistance by erythromycin/clindamycin combination test according to CLSI standard
Testing of highly effective antibiotics like vancomycin, linezolid, tigecycline, daptomycin and ceftaroline as therapeutic options in case of extreme multi-resistance
Test interpretation according to EUCAST and CLSI standard

Susceptibility testing of Enterococci

Ampicillin MIC: detection of ampicillin resistance
Detection of the phenotypic glycopeptide resistance pattern of vancomycin resistant Enterococci by determination of the MIC via teicoplanin and vancomycin
Differentiation betweenEnterococcus faeciumandEnterococcus faecalisby determination of the MIC via Synercid®
Detection of HLAR strains through high-level-resistance testing via gentamicin and streptomycin
Testing of highly effective antibiotics as therapeutic options in case of extreme multi-resistance
Test interpretation according to EUCAST and CLSI standard

Susceptibility testing of Pneumococci

Penicillin G MIC: detection of PBP changes
Detection of cefotaxim resistance
Detection of erythromycin resistance
Detection of vancomycin resistance
Moxifloxacin MIC: detection of group IV quinolones resistance
Test of highly effective antibiotics as therapeutic options in case of extreme multi-resistance
Test interpretation according to EUCAST and CLSI standard